Gain Therapeutics (Gain Therapeutics) Change In Inventory : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Gain Therapeutics Change In Inventory?

Gain Therapeutics's change in inventory for the quarter that ended in Mar. 2024 was $0.00 Mil. It means Gain Therapeutics's inventory stayed the same from Dec. 2023 to Mar. 2024 .

Gain Therapeutics's change in inventory for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Gain Therapeutics's inventory stayed the same from Dec. 2022 to Dec. 2023 .

Gain Therapeutics's Total Inventories for the quarter that ended in Mar. 2024 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Gain Therapeutics Change In Inventory Historical Data

The historical data trend for Gain Therapeutics's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gain Therapeutics Change In Inventory Chart

Gain Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Inventory

Get a 7-Day Free Trial

Gain Therapeutics Quarterly Data
	Dec18	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Inventory	Get a 7-Day Free Trial														-	-	-	-	-

Gain Therapeutics Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Gain Therapeutics (NAS:GANX) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Gain Therapeutics's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Gain Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Gain Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=	N/A

Gain Therapeutics Change In Inventory Related Terms

Thank you for viewing the detailed overview of Gain Therapeutics's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Gain Therapeutics (Gain Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gain Therapeutics Inc (NAS:GANX) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

N/A

Address

4800 Montgomery Lane, Suite 220, Bethesda, MD, USA, 20814

Website

https://www.gaintherapeutics.com

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders and oncology. The company has filed four patent applications for novel small molecule drug candidates that are Structurally Targeted Allosteric Regulators (STARs). The company derives revenues from collaboration and licensing agreements.

Executives

Matthias Alder	officer: Chief Operating Officer	C/O MICROMET, INC., 6707 DEMOCRACY BLVD., STE. 505, BETHESDA MD 28017
Charles Evan Ballantyne	officer: Chief Financial Officer	27 HEARTHSTONE ROAD, HOPKINTON MA 01748
Gianluca Fuggetta	officer: Principal Accounting Officer	C/O GAIN THERAPEUTICS, INC., 4800 MONTGOMERY LANE, SUITE 220, BETHESDA MD 20814
Eric I Richman	director	C/O REV CAPITAL II, LLC, 9740 SORREL AVE, POTOMAC MD 20854
Salvatore Calabrese	officer: Chief Financial Officer	C/O GAIN THERAPEUTICS, INC., 4800 HAMPDEN LANE, SUITE 200, BETHESDA MD 20814
Hans Peter Hasler	director	C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Gwen A Melincoff	director	C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Jeffrey Scott Riley	director	C/O ADEONA PHARMACEUTICALS, INC, 3930 VARSITY DRIVE, ANN ARBOR MI 48108
Goldstein Dov A Md	director
Khalid Islam	director	C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Claude Nicaise	director	215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142
Manolo Bellotto	officer: President and General Manager	C/O GAIN THERAPEUTICS, INC., 4800 HAMPDEN LANE, SUITE 200, BETHESDA MD 20814